News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eleven Biotherapeutics (EBIO) Closes Initial Public Offering



2/11/2014 9:58:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares to cover over-allotments. Eleven’s common stock began trading on the NASDAQ Global Market under the ticker symbol “EBIO” on February 6, 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES